English
  1. Home
  2. Stocks
  3. Glaxo Share Price
  • Chart
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • GlaxoSmithKline Pharmaceuticals

    Large Cap
    ₹2,359.55
    +72.55 (3.17%)
    • Advice
    • Hold
    20 May, 2024 12:55 BSE: 500660 NSE: GLAXOISIN: INE159A01016

    Start SIP in GlaxoSmithKline Pharmaceuticals

    Start SIP

    GlaxoSmithKline Pharmaceuticals Performance

    Day Range

    • Low 2,342
    • High 2,401
    ₹ 2,359

    52 Week Range

    • Low 1,277
    • High 2,524
    ₹ 2,359
    • Open Price2,385
    • Previous Close2,287
    • Volume126099

    GlaxoSmithKline Pharmaceuticals Share Price

    • Over 1 Month +26.1%
    • Over 3 Month +4.6%
    • Over 6 Month +49.66%
    • Over 1 Year +82.85%

    GlaxoSmithKline Pharmaceuticals Key Statistics

    P/E Ratio 67.8
    PEG Ratio -20
    Market Cap Cr 39,972
    Price to Book Ratio 22.5
    EPS 40.5
    Dividend 1.4
    Relative Strength Index 76.49
    Money Flow Index 73.49
    MACD Signal 17.89
    Average True Range 83.95
    GlaxoSmithKline Pharmaceuticals Financials
    IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 911805953738782
    Operating Expenses Qtr Cr 656587667597615
    Operating Profit Qtr Cr 255218287141167
    Depreciation Qtr Cr 1817181617
    Interest Qtr Cr 10001
    Tax Qtr Cr 7620814856
    Net Profit Qtr Cr 19345216131131
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 3,5313,318
    Operating Expenses Annual Cr 2,5072,417
    Operating Profit Annual in Cr 901799
    Depreciation Cr 7066
    Interest Annual Cr 22
    Tax Annual Cr 224228
    Net Profit Annual Cr 585608
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 579488
    Cash from Investing Activity Annual Cr 15805
    Cash from Financing Annual Activity Cr -561-1,544
    Net Cash Flow Annual Cr -251
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,7841,753
    Fixed Assets Annual Cr 335350
    Total Non Current Assets Annual Cr 573861
    Total Current Assets Annual Cr 2,9742,467
    Total Assets Annual Cr 3,5483,328
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 105103
    ROE Annual % 3335
    ROCE Annual % 4742
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3028
    Sign Up to Know More
    IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 930805957762787
    Operating Expenses Qtr Cr 673587668618618
    Operating Profit Qtr Cr 257218289144170
    Depreciation Qtr Cr 1817181617
    Interest Qtr Cr 10001
    Tax Qtr Cr 7620824957
    Net Profit Qtr Cr 19446218132133
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 3,5763,352
    Operating Expenses Annual Cr 2,5452,447
    Operating Profit Annual in Cr 909804
    Depreciation Cr 7066
    Interest Annual Cr 22
    Tax Annual Cr 226229
    Net Profit Annual Cr 590617
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 582484
    Cash from Investing Activity Annual Cr 9808
    Cash from Financing Annual Activity Cr -561-1,543
    Net Cash Flow Annual Cr -251
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,7781,741
    Fixed Assets Annual Cr 335350
    Total Non Current Assets Annual Cr 545832
    Total Current Assets Annual Cr 3,0122,494
    Total Assets Annual Cr 3,5573,327
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 105103
    ROE Annual % 3335
    ROCE Annual % 4742
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3028
    Sign Up to Know More
    Invest in GlaxoSmithKline Pharmaceuticals

    GlaxoSmithKline Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹2,359.55
    +72.55 (3.17%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹2,068.23
    • 50 Day
    • ₹2,040.45
    • 100 Day
    • ₹1,993.36
    • 200 Day
    • ₹1,857.08
    • 20 Day
    • ₹2,065.24
    • 50 Day
    • ₹2,002.68
    • 100 Day
    • ₹2,092.14
    • 200 Day
    • ₹1,807.61

    GlaxoSmithKline Pharmaceuticals Resistance and Support

    PIVOT
    ₹2,367.64
    Resistance
    First Resistance 2,393.27
    Second Resistance 2,426.98
    Third Resistance 2,452.62
    RSI 76.49
    MFI 73.49
    MACD Single Line 17.89
    MACD 46.58
    Support
    First Support 2,333.92
    Second Support 2,308.28
    Third Supoort 2,274.57

    GlaxoSmithKline Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 134,719 6,232,101 46.26
    Week 283,122 8,864,550 31.31
    1 Month 176,033 7,879,233 44.76
    6 Month 230,838 12,836,908 55.61

    GlaxoSmithKline Pharmaceuticals Result Highlights

    GlaxoSmithKline Pharmaceuticals Synopsis

    NSE-Medical-Diversified

    Glaxosmithkline Phar is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3216.34 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2023. GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151.
    Market Cap 38,743
    Sales 3,407
    Shares in Float 4.24
    No of funds 261
    Yield 1.58
    Book Value 21.72
    U/D Vol ratio 0.7
    LTDebt / Equity
    Alpha 0.1
    Beta 0.81

    GlaxoSmithKline Pharmaceuticals Shareholding Pattern

    Owner NameMar-24Dec-23Sep-23Jun-23
    Promoters 75%75%75%75%
    Mutual Funds 4.51%4.5%4.81%4.25%
    Insurance Companies 3.25%4.02%5.15%5.97%
    Foreign Portfolio Investors 3.48%2.93%2.5%2.41%
    Financial Institutions/ Banks 0.01%0.01%0.01%0.01%
    Individual Investors 11.27%11.08%10.62%10.57%
    Others 2.48%2.46%1.91%1.79%

    GlaxoSmithKline Pharmaceuticals Management

    Name Designation
    Ms. R S Karnad Chairperson
    Mr. B Akshikar Managing Director
    Dr.(Ms.) S Maheshwari Director
    Mr. S Williams Director
    Mr. P V Bhide Director
    Mr. A N Roy Director
    Mr. D Sundaram Director
    Mr. M Anand Director
    Mr. J Chandy Director

    GlaxoSmithKline Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    GlaxoSmithKline Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2024-05-17 Audited Results & Final Dividend
    2024-02-12 Quarterly Results
    2023-11-09 Quarterly Results
    2023-07-26 Quarterly Results
    2023-05-17 Audited Results & Final Dividend
    Date Purpose Remarks
    2023-06-30 FINAL Rs.32.00 per share(320%)Final Dividend
    2022-07-08 FINAL Rs.30.00 per share(300%)Dividend
    2022-07-08 SPECIAL Rs.60.00 per share(600%)Special Dividend
    2021-07-20 FINAL Rs.30.00 per share(300%)Dividend

    GlaxoSmithKline Pharmaceuticals MF Shareholding

    Name Amount(cr)
    Nippon India Small Cap Fund - Growth 50,423
    Kotak Flexicap Fund Growth 47,466
    ICICI Prudential Value Discovery Fund Growth 42,664
    Nippon India Growth Fund - Growth 26,822
    Kotak Equity Opportunities Fund Growth 21,496

    GlaxoSmithKline Pharmaceuticals FAQs

    What is Share Price of GlaxoSmithKline Pharmaceuticals ?

    GlaxoSmithKline Pharmaceuticals share price is ₹2,359 As on 20 May, 2024 | 12:41

    What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?

    The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹39972.2 Cr As on 20 May, 2024 | 12:41

    What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?

    The P/E ratio of GlaxoSmithKline Pharmaceuticals is 67.8 As on 20 May, 2024 | 12:41

    What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?

    The PB ratio of GlaxoSmithKline Pharmaceuticals is 22.5 As on 20 May, 2024 | 12:41

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.